Methods: Sixteen pregnant women whose 17 fetuses had hyperechogenic bowel were followed by a protocol of offering additional serologic testing, amniocentesis, hyperimmunoglobulin (HIG), serial ultrasounds, and evaluation of their children. Results: Of 17 fetuses with hyperechogenic

bowel, 13 showed hyperechogenic bowel as a single or first ultrasound sign compared to four who showed it concomitantly or after other ultrasound abnormalities appeared (P = 0.02). Of the 17 fetuses with hyperechogenic bowel, nine were treated with HIG. Eight of the nine CX-6258 in vivo were normal at birth and during a follow-up of 3-8 years. One treated fetus is deaf at 4 years of age. A significantly different result (P < 0.0004) occurred among seven untreated fetuses who were each severely affected at 2-7 years BVD-523 of age, and the remaining one died soon after preterm birth. Among seven of nine fetuses (77.8%) of treated mothers the fetal hyperechogenic bowel resolved after HIG administration. There were no significant differences between treated and untreated fetuses for gestational age at maternal infection, gestational age at birth, and birth weight. Conclusion: Hyperechogenic bowel may be a marker of congenital cytomegalovirus

(CMV) disease, which may be prevented by HIG.”
“Imatinib inhibits Bcr-Abl, c-KIT and PDGFR kinases involved in chronic myelogenous leukemia and gastrointestinal stromal tumors. Mice were given imatinib PO (50 mg/kg) or IV (123 mg/kg) and plasma, liver, brain, spleen, kidney disposition profiles analyzed. Plasma t(1/2) was 43 h. IV plasma ADC(0 ->infinity) was 1139 mu g.h/mL, MRT was 4.87 h, Cl was 1.081/h/kg and V-SS was 5.23 l/kg. PO AUC(0 ->infinity) was 12.82 mu g-h/mL, MRT 5.1 h, C-MAX was 6.99 +/- 2.84 mu g/mL, absorption rate constant, K-a was 4348 h(-1), bioavailability was 27.7%, V-SS was 5.51 l/kg. The hepatic extraction ratio was 0384 and the minimum dose fraction absorbed was 0.450. IV AUC(0 ->infinity) tissue-to-plasma ratios were 2.59 (spleen, kidney) and 2.91 (liver) but increased after PO administration in spleen (3.68) IBET762 and kidney (3.49) and decreased in liver (2.75). Liver and kidney

correlations with plasma concentrations suggests perfusion-limited uptake. Spleen counter-clockwise profile suggests non-concentration dependent uptake. Brain penetration was minimal.”
“Objective: To examine long-term behavioral and neurodevelopmental outcome of children born growth restricted and exposed to hypertension in utero at 9 years of age. Methods: Somatic growth and neurocognitive outcomes were evaluated at age 9-10 years of age in 42 children born with intra uterine growth restriction (IUGR) after pregnancies complicated by hypertensive disorder (17 with maternal preeclampsia and 25 after gestational hypertension). This study group was compared to a control group of 78 IUGR children born after normotensive pregnancy.